WCM
ARCT icon

Winthrop Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Winthrop Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-736
Closed -$10K – 339
2025
Q2 		$10K Buy
+736
New +$8.7K ﹤0.01% 226

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Winthrop Capital Management's ARCT Position: Q3 2025 in Review

Winthrop Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 736 shares — an estimated $10K sold.

Winthrop Capital Management first reported a position in ARCT in Q2 2025 and held it in 1 quarter. The position peaked at $10K in Q2 2025. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Winthrop Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Winthrop Capital Management sold 736 Arcturus Therapeutics shares in Q3 2025, an estimated $10K.
  • Winthrop Capital Management first reported a position in Arcturus Therapeutics in Q2 2025 and held it in 1 quarter.
  • Winthrop Capital Management's Arcturus Therapeutics position peaked at $10K in Q2 2025.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Winthrop Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.